Herpes Virus-6 and Epilepsy

NCT00085683 | Completed

• 2 other identifiers: 04020904-N-0209
• Study Type: observational
• Target: 45
• Locations: 1 country
• Sites: 1

Brief Summary

This study will explore whether the human herpes virus-6 is associated with epileptic seizures. The virus may be involved in brain scarring, called mesial temporal sclerosis, which is seen in some epilepsy patients. The virus is also thought possibly to interfere with neurotransmitters - chemicals that brain cells use to communicate with each other. This study will measure levels of two of these chemicals, GABA and glutamate, which are believed to play a role in the development of seizures. Patients with epilepsy, with or without mesial temporal sclerosis, and healthy control subjects 18 years of age and older may be eligible for this study. Control subjects may not be taking any medication on a regular basis. Epilepsy patients may take only phenytoin, carbamazepine, oxcarbazepine, lamotrigine, or levetiracetam. Candidates are screened with a physical examination and blood tests. Participants have blood drawn and undergo magnetic resonance imaging (MRI) and lumbar puncture (spinal tap). Blood Draw Up to four teaspoons of blood are drawn through a needle in the arm for this study. MRI MRI uses a magnetic field and radio waves to produce pictures of the brain. The scanner is a metal cylinder surrounded by a strong magnetic field. During the scan, the subject lies on a bed that slides into the cylinder, wearing earplugs to muffle loud noises the machine makes when the magnetic fields are switched. The scan takes about 90 to 120 minutes, during which time the subject can communicate with the technician. Lumbar Puncture For this test the subject sits upright or lies on his or her side with knees curled at the chest. A local anesthetic is injected at the lower back, and a needle is inserted in the space between the bones where the cerebrospinal fluid circulates below the spinal cord. A small amount of fluid is collected through the needle. Collection of the fluid usually takes from 5 to 20 minutes.

Conditions

Epilepsy

Keywords

Magnetic Resonance Spectroscopy; Lumbar Puncture; Healthy Control Subjects; Mesial Temporal Sclerosis; Neuroexcitotoxicity; Seizure Disorder; Epilepsy; Healthy Volunteer; HV

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• All patients will have a seizure disorder as documented by EEG and video-EEG. Half of the patients will have radiologically documented mesial temporal sclerosis and the other half will have a brain MRI without mesial temporal sclerosis. The patients can only be on phenytoin, carbamazepine, oxcarbazepine, lamotrigine or levetiracetam, since these anti-epileptic drugs have the least or no effect on the glutamate and GABA levels in the brain. The patients can not take any other medications.
• Healthy control subjects entering the study must be free of serious disease as determined by a standard physical and neurological examination. The control subjects can not be on any medication.
• All subjects must be able to give informed consent allowing us to use the cerebrospinal fluid and serum for research.
• All subjects will have to be able to refrain from chocolate, tea and coffee (low monoamine diet; Wood et al.1979) and alcohol during the one week before the study.
• Patients must be seizure free for 48 hours prior to the lumbar tap and the MRS.

You may not qualify if:

• Subjects will be excluded if:
• They are under the age of 18
• They are female and are pregnant
• They have a history of medical disorders which can affect the concentration of cerebral metabolites, including diabetes mellitus, renal dysfunction, hepatic dysfunction and electrolyte abnormality
• They take any medication for the normal control group
• They take any medication, with the exception of phenytoin, carbamazepine, oxcarbazepine, lamotrigine and levetiracetam for the epilepsy patients
• They have a history of psychiatric and/or mood disorders
• They have implanted devices such as pacemakers, medication pumps or defibrillators, or metal in the cranium except for the mouth, intra-cardiac lines, a history of shrapnel injury or any other condition/device that may be contraindicated or prevent the acquisition of MRI
• They have a coagulopathy that prevents them from having a lumbar puncture performed
• They have had a seizure 48 hours prior to the MRS and the lumbar tap
• Subjects who cannot give informed consent allowing us to use the removed fluid for research will also be excluded.

Sponsors & Collaborators

• National Institute of Neurological Disorders and Stroke (NINDS): lead

Study Sites (1)

National Institute of Neurological Disorders and Stroke (NINDS)

Bethesda, Maryland, 20892, United States

Location

Related Publications (3)

• Aronica E, Yankaya B, Jansen GH, Leenstra S, van Veelen CW, Gorter JA, Troost D. Ionotropic and metabotropic glutamate receptor protein expression in glioneuronal tumours from patients with intractable epilepsy. Neuropathol Appl Neurobiol. 2001 Jun;27(3):223-37. doi: 10.1046/j.0305-1846.2001.00314.x.

  PMID: 11489142 BACKGROUND

• Asano Y, Yoshikawa T, Kajita Y, Ogura R, Suga S, Yazaki T, Nakashima T, Yamada A, Kurata T. Fatal encephalitis/encephalopathy in primary human herpesvirus-6 infection. Arch Dis Child. 1992 Dec;67(12):1484-5. doi: 10.1136/adc.67.12.1484.

  PMID: 1336954 BACKGROUND

• Bernasconi N, Andermann F, Arnold DL, Bernasconi A. Entorhinal cortex MRI assessment in temporal, extratemporal, and idiopathic generalized epilepsy. Epilepsia. 2003 Aug;44(8):1070-4. doi: 10.1046/j.1528-1157.2003.64802.x.

  PMID: 12887438 BACKGROUND

MeSH Terms

Conditions

Epilepsy; Hippocampal Sclerosis

Condition Hierarchy (Ancestors)

Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Malformations of Cortical Development, Group I; Malformations of Cortical Development; Nervous System Malformations; Congenital Abnormalities; Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Design

• Study Type: observational
• Sponsor Type: NIH

Study Record Dates

• First Submitted: June 10, 2004
• First Posted: June 11, 2004
• Study Start: June 1, 2004
• Study Completion: July 1, 2005
• Last Updated: March 4, 2008

Record last verified: 2005-07

Locations

US (1)